https://tonic.inserm.fr/wp-content/uploads/2019/06/equipe-femme-defaut-150x150.jpg
 

Christine BREFEL-COURBON

CU/PH

    Publications rédigées ou co-rédigées

  • > 32- Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM).

    Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C; PREDI-STIM study group.

    J Parkinsons Dis. 2020 May 16. doi: 10.3233/JPD-191903.
  • > 39- Programming parameters of subthalamic deep brain stimulators in Parkinson’s disease from a controlled trial.

    Knudsen K, Krack P, Tonder L, Houeto JL, Rau J, Schade-Brittinger C, Hartmann A, Hälbig T, Paschen S, Barbe MT, Kühn A, Fraix V, Brefel-Courbon C, Vesper J, Maltête D, Sixel-Döring F, Weiss D, Witjas T, Thobois S, Agid Y, Schnitzler A, Schuepbach WMM, Timmermann L, Damier P, Vidailhet M, Deuschl G; EARLYSTIM study group.

    Parkinsonism Relat Disord. 2019 Jun 18. pii: S1353-8020(19)30244-5. doi: 10.1016/j.parkreldis.2019.05.023.
  • > 29- Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study.

    Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M.

    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27727.
  • > 22- How to diagnose parkinsonian central pain?

    Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C.

    Parkinsonism Relat Disord. 2019 May 1. pii: S1353-8020(19)30220-2. doi: 10.1016/j.parkreldis.2019.04.025.
  • > 63- Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.

    Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG.

    Parkinsonism Relat Disord. 2019 Jun;63:199-203. doi: 10.1016/j.parkreldis.2019.02.006. Epub 2019 Feb 5.
  • > 20- Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson’s disease cohort?

    Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B; NS-Park/F-CRIN Network study group.

    Parkinsonism Relat Disord. 2019 Apr 25. pii: S1353-8020(19)30207-X. doi: 10.1016/j.parkreldis.2019.04.012.
  • > 58- Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease With Early Motor Complications.

    Barbe MT, Tonder L, Krack P, Debû B, Schüpbach M, Paschen S, Dembek TA, Kühn AA, Fraix V, Brefel-Courbon C, Wojtecki L, Maltête D, Damier P, Sixel-Döring F, Weiss D, Pinsker M, Witjas T, Thobois S, Schade-Brittinger C, Rau J, Houeto JL, Hartmann A, Timmermann L, Schnitzler A, Stoker V, Vidailhet M, Deuschl G; EARLYSTIM study group.

    Mov Disord. 2019 Nov 22. doi: 10.1002/mds.27892.
  • > 57- Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.

    Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.

    Neurology. 2019 Mar 5;92(10):e1109-e1120. doi: 10.1212/WNL.0000000000007037. Epub 2019 Feb 8. Erratum in: Neurology. 2019 Jun 11;92(24):1166.
  • > 7- Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.

    Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig T, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.

    Neurology. 2019 Feb 8. pii: 10.1212/WNL.0000000000007037. doi: 10.1212/WNL.0000000000007037.
  • > 6- Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson’s disease: a correlation study.

    Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, Kas A, Salabert AS, Ory-Magne F, Payoux P, Brefel-Courbon C.

    J Neural Transm (Vienna). 2019 Jan 31. doi: 10.1007/s00702-019-01974-5.
  • > 55- LRP10 in α-synucleinopathies.

    Tesson C, Brefel-Courbon C, Corvol JC, Lesage S, Brice A; French Parkinson’s Disease Genetics Study Group.

    Lancet Neurol. 2018 Dec;17(12):1034. doi: 10.1016/S1474-4422(18)30400-9. Epub 2018 Nov 13.
  • > 62- Centers for the management of Parkinson’s disease.

    Brefel-Courbon C, Rémy P.

    Rev Prat. 2018 May;68(5):520-521. French.
  • > 48- Molecular Imaging of Opioid System in Idiopathic Parkinson’s Disease.

    Thobois S, Brefel-Courbon C, Le Bars D, Sgambato-Faure V.

    Int Rev Neurobiol. 2018;141:275-303. doi: 10.1016/bs.irn.2018.07.029.
  • > 28- Cognitive complaint in early Parkinson’s disease: A pilot study.

    Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.

    Acta Neurol Scand. 2018 Jan;137(1):59-66. doi: 10.1111/ane.12808. Epub 2017 Aug 22.
  • > 66- Abnormal pain perception in patients with Multiple System Atrophy.

    Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C.

    Parkinsonism Relat Disord. 2017 Dec 8. pii: S1353-8020(17)30827-1. doi: 10.1016/j.parkreldis.2017.12.001.
  • > 41- Cognitive complaint in early Parkinson’s disease: A pilot study.

    Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.

    Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12808.
  • > 45- Parkinson’s patients can rely on perspective cues to perceive 3D space.

    Séverac Cauquil A, Ory-Magne F, Jardiné V, Galitzky M, Rosito M, Brefel-Courbon C, Celebrini S.

    Brain Res. 2017 May 15;1663:161-165. doi: 10.1016/j.brainres.2017.03.017. Epub 2017 Mar 19.
  • > 18- Other care in Parkinson’s disease: Psychological, rehabilitation, therapeutic education and new technologies.

    Dupouy J, Ory-Magne F, Brefel-Courbon C.

    Presse Med. 2017 Mar;46(2 Pt 1):225-232. doi: 10.1016/j.lpm.2016.11.009. Epub 2016 Dec 28. Review. French.
  • > 14- A longitudinal follow-up study of the quantification of dopamine transporters with 123I-Ioflupane (DaTscan)

    H. Fayolle, P. Gantet, A.S. Salabert, J. Delrieu, C. Brefel-Courbon, F. Ory-Magne, T. Voisin, P. Payoux

    Médecine Nucléaire 41 (2017) 36-41
  • > 56- Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial.

    Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, Bérard E, Bourrel R, Molinier L, Brefel-Courbon C.

    PLoS One. 2016 Sep 29;11(9):e0162646. doi: 10.1371/journal.pone.0162646.
  • > 51- Case report of Lewy body disease mimicking Creutzfeldt-Jakob disease in a 44-year-old man.

    Saint-Aubert L, Pariente J, Dumas H, Payoux P, Brandel JP, Puel M, Vital A, Guedj E, Lesage S, Peoc’h K, Brefel Courbon C, Ory Magne F.

    BMC Neurol. 2016 Jul 30;16:122. doi: 10.1186/s12883-016-0643-y.
  • > [A therapeutic educational program in Parkinson’s disease: ETPARK].

    Ory Magne F, Arcari C, Canivet C, Sarrail M, Fabre MH, Mohara C, Brefel Courbon C.

    Rev Neurol (Paris). 2014 Feb;170(2):128-33. doi: 10.1016/j.neurol.2013.08.007. French.
  • > Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.

    Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network..

    Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050.